

i

PROCEDURES FOR PRIOR AUTHORIZATION

Completed forms can be faxed in confidence to 1-514-286-8480 for residents of Quebec and 1-844-661-2640 for residents of all other provinces

Upon receipt, this request will be confidentially reviewed according to payment criteria developed by Medavie Blue Cross in consultation with independent health care consultants. In some cases, additional clinical or diagnostic information may be required to process your claim.

For Quebec residents, the criteria for prior authorization are adjusted to meet the requirements of the Régie de l'assurance maladie du Québec (RAMQ).

- Prior Authorization is a pre-approval process to determine if certain products will be reimbursed under a member's benefit plan.
- Please complete entire form. Incomplete forms cannot be processed.
- For certain medications, approval for reimbursement may be conditional on confirmation of enrollment in the patient support program.
- Prior Authorization may be limited to a specified period or quantity of medication.
 Some Medavie Blue Cross plans may require you to purchase a drug requiring prior authorization from a preferred pharmacy*. If your prior authorization request is approved, a case manager may contact you, your physician, or Patient Assistance Program to provide information about the program and to arrange to have your prescription transferred to the preferred pharmacy.
 - *Not applicable in Quebec.
- In cases where a request for Prior Authorization is declined, Medavie Blue Cross is denying payment for a product and is not challenging the medical opinion of the physician nor rendering a medical opinion.
- Any costs associated with the completion of this form or obtainment of additional medical information are the responsibility of the member.
- Renewal of the Prior Authorization will be considered by Medavie Blue Cross upon request from the patient/member. The renewal request should include information from the physician supporting continued use of the medication.
- Prior Authorization coverage is contingent on your continued status as a Medavie Blue Cross cardholder or beneficiary.
- If this is a request under the *Mesure du patient d'exception* for a Quebec resident, please include a completed *Patient d'exception* form that can be found here: www.medaviebc.ca/en/resources, in addition to this document.
- If you would like more information about our Patient First Network, including how your Patient Support Program can become integrated with our new enhanced Prior Authorization processes, please send an e-mail to: patientfirstnetwork@medavie.bluecross.ca.

ee of





1 PHARMACY INFORMATION	
This section is to be completed by the Professional coordinating the re Pharmacy)	quest on behalf of the member (PSP, Cancer Care Navigator or
Decision communication preference:	Telephone, Number:
Name of Program/Pharmacy:	
Contact Name:	Contact E-mail:
2 PATIENT INFORMATION	
Part A	
Patient Name:	Date of Birth:
E-mail address of patient (or of legal guardian if patient is underage):	(mm/dd/yyyy)
Address:	Suite: City:
Province: Postal Code:	Telephone Number:
Policy Number: ID Number:	
Do you have valid Medicare coverage in your current province of residence?	☐ Yes ☐ No
Have you already purchased this prescription?	☐ Yes ☐ No
Please attach your paid-in-full receipt with this request form. If you have alre your receipt to Medavie Blue Cross, please indicate the date of the oldest receipt to Medavie Blue Cross, please indicate the date of the oldest receipt to Medavie Blue Cross, please indicate the date of the oldest receipt to Medavie Blue Cross, please indicate the date of the oldest receipt to Medavie Blue Cross, please indicate the date of the oldest receipt to Medavie Blue Cross, please indicate the date of the oldest receipt to Medavie Blue Cross, please indicate the date of the oldest receipt to Medavie Blue Cross, please indicate the date of the oldest receipt to Medavie Blue Cross, please indicate the date of the oldest receipt to Medavie Blue Cross, please indicate the date of the oldest receipt to Medavie Blue Cross, please indicate the date of the oldest receipt to Medavie Blue Cross, please indicate the date of the oldest receipt to Medavie Blue Cross, please indicate the date of the oldest receipt to Medavie Blue Cross, please indicate the date of the oldest receipt to Medavie Blue Cross, please indicate the date of the oldest receipt to the oldest receipt	
Part B – Coordination of Benefits	
Do you or any dependant have coverage for this drug under any other plan	or program?
Policy Number:	Carrier:
(If applicable, please attach Explanation of Benefits from prior carrier with complete for	m)
If the patient is a dependent, provide the birth day and month of the cardhold	ler for the other carrier:(mm/dd)
Public-Funded Program – Have you applied for coverage through a public-fu	
If No, please indicate why:	
Part C – Authorization	
	d and used by Medavie Blue Cross to administer the terms of my policy or the ducts and services that I am eligible for as a member of a policy, and other nent at www.medaviebc.ca.
released to following third parties as required for the purposes of administe	ch as claim, health and/or financial related data may be collected from and/or tring and managing the benefits outlined in the policy of which I am an eligible surance companies, regulatory authorities and investigative bodies, services nt.
Where allowed by law, my information may be shared with Medavie Blue collected. If I am a resident of Quebec, this includes transferring or disciproviders outside of that province.	Cross employees or service providers in jurisdictions other than where it was osing my personal information to Medavie Blue Cross employees or service
I understand that my consent is only valid for the time it is needed to achieve my consent at any time. However, in some instances doing so may preven may be useful to me and/or my dependents. This consent complies with federal consent	the purposes outlined herein, unless I withdraw it. I understand I may withdraw t Medavie Blue Cross from providing me with certain products or services that eral and provincial privacy laws.
For more details about our information practices, including how your persor you have concerns or questions, please see our Medavie Blue Cross Privacy	nal information is protected, how to access or correct personal information, or if y Statement available at www.medaviebc.ca or call 1-800-667-4511.
Signature of Patient:	Date:

Residents of All Other Provinces
PO BOX 220, MONCTON (NB) E1C 8L3
TEL.: 1-800-667-4511 FAX: 1-844-661-2640

Residents of Quebec PO BOX 3300, STATION B, MONTREAL (QC) H3B 4Y5 TEL.: 1-888-588-1212 FAX: 1-514-286-8480



3 SPECIALTY DRUG INFORM				D. (. (D.))
Name of patient: Policy Number:				Date of Birth:
3A Patient Support Program (PS	-			
Indicate the name of the Patient Su PSP phone #:				
T OF PRIORIC #.			1 01 1 αλ π.	
Product Name	Strength	Dosage		Diagnosis
Patient weight:				:
Date treatment was initiated:	(mm/dd/yyyy)		Expected duration of treat	ment:
Date of diagnosis:	/dd/yyyy)		Was treatment initiated in	hospital?
Where is medication being admini				
Indicate the specialty of the physic				
Indicate if the disease or injury is v	work related: 🗌 Ye	s 🗌 No		
For Initial Request, please compl	ete sections 3B and	d 3D. For Renev	wals, please complete sec	ctions 3C and 3D.
3B Initial Request				
Is the drug being prescribed according to the stress of th		n Canada produ	ct monograph?	□ No
☐ Left Eye ☐ Right Eye				
Indicate whether the drug will be us	ed 🗌 as monother	apy or 🔲 in as	sociation with (specify):	
If the request is for Lucentis, please	e provide a clinical ra	itionale for avoid	ing the use of a biosimilar v	ersion of ranibizumab:
	•			
Depending on the diagnosis, please	e answer the indicate	ed numbered au	estions:	
☐ Visual deficiency due to macular		·		2 - 3 - 4
☐ Visual deficiency due to macular	-		, ,	
☐ Visual deficiency caused by diab	-			_ ` .
☐ Age-related macular degeneration		,	al neovascularization (CNV)): 4 - 5 - 6 - 7
☐ Visual deficiency due to choroida	al neovascularizatior	n (CNV) seconda	ary to pathologic myopia (PN	И): 1 - 8 - 9 - 10
Optimal visual acuity after co		veen 6/12 and 6/	/96 ☐ Between 6/12 an	d 6/120 ☐ Between 6/9 and 6/96
		er (specify):		_
2. Thickness of the central retin	na: µm			
Afferent pupillary defect: [☐ Absent ☐ Pres	sent		
4. Diagnosis confirmed by: [Retinal (fluoresce	in) angiography	Optical coherence ton	nography
5. Linear dimension of the lesion	on: (dis	sc areas)		
6. Centre of the macula – Sign	ificant permanent str	ructural damage:	Absent Presen	t
				(see next page

3	SPECIALTY DRUG INFORMATION
	me of patient: Date of Birth:
	licy Number: ID Number:
E-r	nail address of patient or of legal guardian if patient is underage:
3B	Initial Request (cont'd)
7.	Disease progression in the last three months, confirmed by: Retinal (fluorescein) angiography Optical coherence tomography Recent changes in visual acuity Other (specify):
8.	Measure of the myopia in diopters:
9.	Intraretinal or subretinal fluid or active leakage secondary to choroidal neovascularization: Absence Presence confirmed by retinal (fluorescein) angiography Presence confirmed by optical coherence tomography
10	Presence of one of the following related health problems: Active or suspected ocular or periocular infections Active intraocular inflammation No related health problem
3C	Renewal Request
Plea	se provide information on the evolution of the disease to evaluate the response to treatment.
Da	te of initial evaluation (pretreatment): Date of most recent evaluation: (mm/dd/yyyy)
	eft Eye 🔲 Right Eye
	e request is for Lucentis and the patient is new to Medavie Blue Cross, please indicate whether this medication was reimbursed by their rious insurer: Yes No
Dep	ending on the diagnosis, please answer the indicated numbered questions:
•	/isual deficiency due to macular edema secondary to central retinal vein occlusion (CRVO): 1 - 2 - 5 - 7
	isual deficiency due to macular edema secondary to branch retinal vein occlusion (BRVO): 1 - 2 - 5 - 7
	/isual deficiency caused by diabetic macular edema (DME): 1 - 2 - 5 - 7
	age-related macular degeneration (AMD) in the presence of choroidal neovascularization (CNV): 1 - 3 - 5 - 7
□ \	isual deficiency due to choroidal neovascularization (CNV) secondary to pathologic myopia (PM): 3 - 4 - 5 - 6
1.	Visual acuity measured using the Snellen chart: ☐ Stabilization ☐ Improvement ☐ Deterioration
2.	Macular edema: Stabilization Improvement Deterioration
3.	Response to treatment: Stabilization Improvement Deterioration
4.	Disease is still active: No Yes, specify: Reduced visual acuity Signs of lesion activity Other. Specify:
5.	Response to treatment confirmed by: Retinal (fluorescein) angiography Optical coherence tomography Clinical examination
	(see next page)

3	SPECIALTY DRUG INFORMATION				
Nam	e of patient:			Date of Birth:	
Polic	y Number:		D Number:		
E-ma	ail address of patient or of legal guardian if patient is ι	underage:			
3C R	Renewal Request (cont'd)				
6.	If stabilization obtained, indicate if patient has one of the following situations:	☐ Vision imp	econdary to PM, a	letters ble to intraretinal or subretinal fluid, or as assessed by OCT and/or FA	
7.	Best corrected visual acuity: Stabilization	Improvement	☐ Deterioration	า	
3D A	Additional Information				
	Please indicate any additional information pertaining	to this request	i.		





First Name:	Last Name:	Permit Number:
Specialty:		
Clinic Name:		
Address:		Suite:
City:	Province:	Postal Code:
E-mail:	Telephone:	Fax:
Signature:		Date:
		(mm/dd/yyyy)

Residents of All Other Provinces
PO BOX 220, MONCTON (NB) E1C 8L3
TEL.: 1-800-667-4511 FAX: 1-844-661-2640

No.